葫芦娃：获得盐酸左沙丁胺醇雾化吸入溶液药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of a nebulized solution of Levosalbutamol, which is intended for the treatment or prevention of bronchospasm in adults and children over 6 years old [1] Group 1 - The product is an inhalation formulation that has not been previously marketed in China [1] - A total of 22 other companies have also received approval for similar products in the domestic market [1] - The company has invested a total of 5.7097 million yuan in research and development for this product [1] Group 2 - There is uncertainty regarding the sales performance of the drug [1]